Medtronic's Endurant 'AAA' Stent Graft Shows Sustained Durability in Complex Patients

Tue Apr 9, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

Analysis of ENGAGE Registry Found Similarly Strong Outcomes with Device for Endovascular Treatment
of Abdominal Aortic Aneurysms in Short and Standard Neck Lengths

MINNEAPOLIS -- April 9, 2013 -- Presented to endovascular specialists at the 35th Charing Cross
International Symposium in London, a new analysis of clinical data on the Endurant AAA Stent Graft
System from Medtronic, Inc. (NYSE: MDT) demonstrates the implanted medical device's consistent and
compelling performance in treating abdominal aortic aneurysms across a range of patient anatomies,
from relatively straightforward to highly complex.

This subset analysis of the international ENGAGE registry for the Endurant AAA Stent Graft, the
market-leading device in its product category worldwide, compared the influence of neck length on
patient outcomes. Specifically, the two-year data demonstrated similarly strong outcomes in
patients with neck lengths of 10mm to 15mm (short) and greater than 15mm (standard). Historically,
shorter neck lengths have been associated with limited eligibility for endovascular repair and
higher rates of adverse events.

"The Endurant AAA Stent Graft System continues to demonstrate durable performance for endovascular
repair of abdominal aortic aneurysms in a variety of clinical and anatomical scenarios," said
presenter Prof. Hence Verhagen, chief of vascular surgery at the Erasmus Medical Center in
Rotterdam, the Netherlands. "This specific subset analysis of the ENGAGE Registry adds to the
already large body of clinical evidence on this remarkably versatile device, which closes the
outcomes gap between patients with short and standard neck lengths."

The analysis included 123 patients with neck lengths of 10-15mm, 226 patients with neck lengths of
15-20mm and 873 patients with neck lengths of greater than 20mm. The two-year results demonstrated
no statistically significant differences across these three groups on any of the following

*type I endoleak (0.0%, 0.0%, 0.7%)
*stent graft migration (0.0%, 0.0%, 0.0%)
*aneurysm rupture (0.0%, 0.0%, 1.1%)
*conversion to open surgery (0.0%, 0.0%, 1.1%)
*secondary procedures (4.2%, 6.3%, 6.6%)

In this context, neck length is the span of healthy aortic tissue between the top of the aneurysm
and the lowest renal artery, which cannot be safely occluded. Neck length determines how much of a
landing zone is available for the proximal end of the stent graft. The Endurant AAA Stent Graft is
approved for use in patients with neck lengths of 10mm or greater.

The ENGAGE registry has enrolled more than 1,200 patients at more than 80 sites across six
continents since the Endurant AAA Stent Graft System received the CE (Conformité Européenne) mark
in June 2008. With five-year follow-up planned for all patients, it represents the most robust
long-term study of any stent graft ever initiated.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers
the broadest range of innovative medical technology for the interventional and surgical treatment
of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and
services that deliver clinical and economic value to healthcare consumers and providers around the

Medtronic, Inc. ( ), headquartered in Minneapolis, is
the global leader in medical technology -- alleviating pain, restoring health and extending life
for millions of people around the world. 

Any forward-looking statements are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results
may differ materially from anticipated results.

- end -


Joseph McGrath
Public Relations

Jeff Warren
Investor Relations


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE